<DOC>
	<DOC>NCT03037203</DOC>
	<brief_summary>This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.</brief_summary>
	<brief_title>A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Disorders of Excessive Somnolence</mesh_term>
	<criteria>1. Diagnosis of idiopathic PD according to the UK PDS Brain Bank Criteria. 2. Hoehn and Yahr stage 1, 2, or 3. 3. Baseline ESS score &gt;10. 4. Baseline mean sleep latency of â‰¤20 minutes on the MWT. 1. Diagnosis of other degenerative Parkinsonian syndromes (e.g., progressive supranuclear palsy, multiple system atrophy [MSA], or dementia with Lewy bodies [DLB]). 2. Usual nightly time in bed of &lt;6 hours, including the night before the Baseline visit. 3. Prior or documented history of moderate or severe obstructive sleep apnea (OSA). 4. Has evidence at screening of severe cognitive impairment or has cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>